Discussion
NSCLC
NSCLC
Recent remarkable advances in molecular targeted therapies for advanced NSCLC harboring mutations such as In this trial, unecritinib demonstrated promising antitumor activities in advanced NSCLC patients with Previous studies showed that NSCLC patients with Accurate delineation of targetable oncogenic alterations is critical to the targeted therapies for NSCLCThe safety profile of unecritinib is overall consistent with that of other ROS1 inhibitors. The rate of drug dose interruptions due to TRAEs was 37.5% in the patients who received unecritinib 300 mg BID, which is higher than that (22.8%) of crizotinib.A previous pharmacokinetics analysis of quantifiable unecritinib and unecritinib M data from 40 subjects after oral administration of unecritinib showed that unecritinib pharmacokinetics could be explained by a 1-compartment model with first-order absorption and elimination for unecritinib coupled with a 2-compartment model with time-dependent clearance for the metabolite.Overall, this study demonstrated that unecritinib had an acceptable safety profile and established the clinical benefit of unecritinib for ROS1 inhibitor-naive patients with 